Patents Examined by Satyanarayana R. Gudibande
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9981014
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 29, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9981016
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 29, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Glycopeptide compound or pharmaceutical salt thereof and method for preparing same, and pharmaceutical compositions and applications thereof
    Patent number: 9982019
    Abstract: The present invention provides a glycopeptide compound or pharmaceutically acceptable salt thereof as shown in Formula (I) or (II), and a method for preparing same, and pharmaceutical compositions and applications thereof, wherein the definition of R1, R2, R3, R4, R5 is the same as that of the specification. The glycopeptide compound of the present invention has in-vitro antibacterial activity and has important significance for development of new antibacterial agents.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: May 29, 2018
    Inventors: Dingfeng Zhang, Yuanyuan Ge, Mei Ge, Weicheng Zhou, Wei Wei, Shunli Zhang, Lingao Ruan, Zhenren Liu, Chang Shao
  • Immunoregulatory peptides and methods of use
    Patent number: 9974853
    Abstract: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-? secretion through interaction with toll-like receptors. Experiments are described illustrating the efficacy of the compounds in treating otitis media.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: May 22, 2018
    Assignee: 13THERAPEUTICS, INC.
    Inventors: Sharon L. McCoy, Steven H. Hefeneider
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9974837
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 22, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9974836
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 22, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9974838
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 22, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9974835
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 22, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Coupling method for peptide synthesis at elevated temperatures
    Patent number: 9969769
    Abstract: An improved method for coupling amino acids into peptides or peptidomimetics is disclosed that includes the steps of combining an amino acid, a carbodiimide, an activator additive, and a base at less than 1 equivalent compared to the amino acid to be activated; and carrying out the activation and coupling at a temperature greater than 30° C.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: May 15, 2018
    Assignee: CEM CORPORATION
    Inventors: Jonathan M. Collins, Sandeep Kumar Singh
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9968656
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 15, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9968655
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 15, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9968658
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 15, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Compositions and methods for modulation of immune function
    Patent number: 9969784
    Abstract: Compositions and methods for modulating immune cell function and Nedd-4 family member signaling are disclosed.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: May 15, 2018
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Paula M. Oliver, Christopher R. Riling
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9968657
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 15, 2018
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Use of antisecretory factors (AF) for optimizing cellular uptake
    Patent number: 9962424
    Abstract: The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: May 8, 2018
    Assignee: LANTMÄNNEN AS-FAKTOR AB
    Inventors: Eva Jennische, Stefan Lange, Hans-Arne Hansson
  • Process for producing self-assembling peptide derivatives
    Patent number: 9963483
    Abstract: An object of the present invention is to provide a process capable of producing a self-assembling peptide derivative that is useful in the fields of regenerative medicine and surgery in large quantities and in an economical and efficient manner. In particular, provided is a production process employing a combination of (i) a step of convergently constructing a sequence with use of a common repeating unit consisting of a specific amino acid sequence and (ii) a step of first isolating the peptide derivative as a disulfuric acid salt, a tetramethanesulfonic acid salt or a tetra(trifluoroacetic acid (TFA) salt), and then subjecting the peptide salt to a salt exchange reaction to yield a tetrahydrochloric acid salt.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: May 8, 2018
    Assignee: MENICON CO., LTD.
    Inventors: Hidenori Yokoi, Yasuhiro Yokoyama, Keisuke Matsuyama, Kenichiro Yamamoto, Kinsei Anzai, Daisuke Nakamura, Toyohiro Nagano, Kazuya Kodama
  • Cross-linked poly-E-lysine non-particulate support
    Patent number: 9938378
    Abstract: The invention provides a non-particulate cross-linked poly-?-lysine polymer. The poly-?-lysine and cross linker are linked by amide bonds and may the cross linker has at least two functional groups capable of reacting with an alpha carbon amine of poly-?-lysine. The polymer is suitably insoluble in water and other solvents and is provided in macro form for example a sheet, article or fiber. The macro form polymer is useful in a wide range of applications including wound treatment, as a medical diagnostic comprising a particulate support and a functional material bound or retained by the support and solid phase synthesis of peptides, oligonucleotides, oligosaccharides, immobilization of species, cell culturing and in chromatographic separation.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: April 10, 2018
    Assignee: SPHERITECH LTD
    Inventor: Donald Wellings
  • Synthetic apelin fatty acid conjugates with improved half-life
    Patent number: 9931372
    Abstract: The invention provides a conjugate, or a pharmaceutically acceptable salt thereof, comprising a synthetic polypeptide of Formula I: Q-R-P-R-L-C*-H-K-G-P-(Nle)-C*-F??(I) or a amide or ester thereof; and a fatty acid selected from: wherein said fatty acid is covalently linked to the N-terminus of the peptide via one of its carboxylic acid functionality, optionally via a polyethylene glycol linker; and wherein the two cysteine amino acids labeled with “*” form a disulfide bond between the thiol functionalities of their side chain. The conjugates are agonist of the APJ receptor.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: April 3, 2018
    Assignee: NOVARTIS AG
    Inventors: Aaron Kanter, Aimee Richardson Usera, Frederic Zecri
  • Compositions comprising the NC2 domain of collagen IX and methods of using same
    Patent number: 9932390
    Abstract: The present invention relates to the newly identified timerization initiating and stagger determining capacity of the NC2 domain of collagen IX. The invention further relates to a hexavalent molecular building block wherein the linkage of additional moieties to the amino and carboxyl terminals of monomers comprising the NC2 domain of collagen IX promotes the directed association of those moieties via the trimerization initiating and stagger determining capacity of the NC2 domain of collagen IX.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: April 3, 2018
    Assignee: SHRINERS HOSPITAL FOR CHILDREN
    Inventors: Hans Peter Bachinger, Sergey P. Budko
  • Medicament for treating olfaction disorder
    Patent number: 9931380
    Abstract: The object of the present invention is to provide an olfactory disturbance therapeutic agent that is effective in repairing or regenerating olfactory epithelium that suffered damages such as scratches and can be administered for a long time. The object of the present invention is achieved by an olfactory disturbance therapeutic agent including at least one active ingredient that is selected from among a group consisting of insulin, insulin analogs, and insulin secretagogues. Preferably, the olfactory disturbance therapeutic agent is used for people with olfactory disturbance who have, or are at risk of having, impaired insulin secretion or insulin resistance, or for people who could suffer an iatrogenic increase in blood sugar level or a disturbance in a balance of adrenocortical hormone stemming from a long-term use of steroid as olfactory disturbance treatment.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: April 3, 2018
    Inventors: Akihito Kuboki, Shu Kikuta